false
0001468929
0001468929
2026-11-12
2026-11-12
0001468929
NXGL:CommonStockParValue0.001Member
2026-11-12
2026-11-12
0001468929
NXGL:WarrantsToPurchaseCommonStockMember
2026-11-12
2026-11-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 12, 2026
| NEXGEL,
INC. |
| (Exact
name of registrant as specified in its charter) |
| Delaware |
|
001-41173 |
|
26-4042544 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification
No.) |
2150
Cabot Boulevard West, Suite B
Langhorne,
Pennsylvania |
|
19047 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (215) 702-8550
(Former
name or former address, if changed since last report)
Not
Applicable
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, par value $0.001 |
|
NXGL |
|
The
Nasdaq Capital Market LLC |
| Warrants
to Purchase Common Stock |
|
NXGLW |
|
The
Nasdaq Capital Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02. Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 12, 2026, the Board
of Directors (the “Board”) of NexGel, Inc.,, a Delaware company (the “Company”),
elected Aviv Argaman as a director, effective immediately, to serve until the Company’s next annual meeting of stockholders and
until his successor is elected and qualified. The Board has determined that Mr. Argaman is an independent director under the Nasdaq Listing
Rules. On November 18, 2026, the Board also appointed Mr. Argaman to the special committee of the Board described in Item 8.01. There
is no arrangement or understanding between Mr. Argaman and any other person under which he was selected as a director, and there are
no family relationships between Mr. Argaman and any director or executive officer of the Company.
Mr.
Argaman, age 36, has been a full-time professional investor since 2021. Since 2024, he has been the founder and manager of Asymmetry
Point Capital LLC, an investment firm that serves as the general partner and investment manager of Asymmetry Point LP, a Delaware limited
partnership (“Asymmetry Point”), and its feeder fund, Asymmetry Point CF I. From 2022 to 2024, he founded and
managed Asymmetry Point Capital Ltd., an Israeli investment firm. Before 2021, he worked in engineering and management consulting. He
holds a double B.Sc. in Electrical Engineering and Physics from the Technion, Israel Institute of Technology.
As previously reported in
the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on November 12, 2026 (the “Prior
Form 8-K”), on November 10, 2026, the Company entered into a Securities Purchase Agreement for a private placement (the
“New Capital Financing”) of its common stock, par value $0.001 per share (“Common Stock”),
and warrants. On the same date, the Company entered into Note Amendment and Conversion Agreements (the “Conversion Agreements”)
with holders (the “Holders”) of its convertible promissory notes issued in 2026 (the “Notes”).
Under the Conversion Agreements, the Notes will convert into Common Stock at a closing (the “Conversion Closing”)
that will occur only upon, and subject to, the completion of a proposed business combination between the Company and Fountainhead LifeSciences
and its affiliates, including Sequence LifeScience, Inc. and NVISION Biomedical Technologies, Inc. (the “Merger”),
and the other conditions described in the Prior Form 8-K. The Company has not entered into a definitive agreement for the Merger. Share
and per-share amounts in this report give effect to the 1-for-20 reverse stock split effective October 12, 2026.
Mr.
Argaman has an indirect interest, through Asymmetry Point, in the following transactions with the Company since January 1, 2025. Asymmetry
Point purchased $2.0 million aggregate principal amount of the Notes in the Company’s private placements of Notes in 2026 (issued
on April 17, 2026 and July 2, 2026), on the same terms as the other investors, including 10% interest, five-year warrants issued with
the Notes (the “Existing Note Warrants”) exercisable for 41,667 shares of Common Stock at an exercise price
of $16.00 per share, and registration rights.
Asymmetry
Point is a Holder and a party to one of the Conversion Agreements, on the same terms as the other Holders. Under it, Asymmetry Point
irrevocably elected to convert its Notes into 363,636 shares of Common Stock at $5.50 per share and to receive approximately 5,868 shares
of Common Stock for interest accrued through September 30, 2026, in each case only upon completion of the Merger and the other conditions
to the Conversion Closing described in the Prior Form 8-K. The exercise price of its Existing Note Warrants was reduced to $13.00 per
share, and the warrants will be surrendered at the Conversion Closing unless Asymmetry Point funds its full pro rata share of the New
Capital Financing. Asymmetry Point also gave the consents, waivers, forbearance and voting agreement described in the Prior Form 8-K.
Asymmetry Point did not participate in the New Capital Financing.
Mr.
Argaman will receive the Company’s standard non-employee director compensation, which has not yet been determined.
Item
8.01. Other Events.
On
November 18, 2026, the Board established a special committee of independent directors (the “Special Committee”)
consisting of Steve Ciardiello (Chair), Jerome Zeldis and Aviv Argaman, to evaluate and negotiate the proposed Merger and make recommendations
to the Board, with customary authority to retain independent legal and financial advisors. The Board has determined that each member
of the Special Committee is independent under the Nasdaq Listing Rules. Each member of the Special Committee other than Mr. Zeldis holds
Notes (in the case of Mr. Argaman, through Asymmetry Point, as described in Item 5.02), which would automatically convert into Common
Stock if the Merger is completed, as described in the Prior Form 8-K.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Date:
November 18, 2026 |
|
|
| |
|
|
| |
NEXGEL,
INC. |
| |
|
|
| |
By: |
/s/
Brian Kieser |
| |
|
Brian
Kieser
Interim
Chief Executive Officer |